The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 17, 2025

Filed:

Jul. 21, 2022
Applicant:

China Pharmaceutical University, Jiangsu, CN;

Inventors:

Xiaoxing Wu, Jiangsu, CN;

Xiaoyu Chen, Jiangsu, CN;

Wenqiang Li, Jiangsu, CN;

Chengxia Shu, Jiangsu, CN;

Guangmei Luo, Jiangsu, CN;

Kexin Yang, Jiangsu, CN;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/55 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 491/107 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/55 (2013.01); A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 491/107 (2013.01); C07D 519/00 (2013.01);
Abstract

The present invention belongs to the field of medicinal chemistry, and particularly relates to synthesis, a preparation method and the use of an inhibitor containing dual targets SHP2 and CDK4/6, wherein the inhibitor comprises three compounds of general formulas I-III and pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs or prodrugs thereof. According to the present invention, a class of brand-new SHP2 and CDK4/6 dual-target inhibitors are prepared by means of a pharmacophore fusion and reasonable drug design method, so that the problems of drug resistance, poor drug effect, etc., of the existing SHP2 inhibitor and CDK4/6 inhibitor are solved; the great significance of the present invention is providing the first SHP2 and CDK4/6 dual-target inhibitor, which provides a basis for solving the problem of drug resistance of kinase and phosphatase in the later period.


Find Patent Forward Citations

Loading…